Navigation Links
New agent strikes at respiratory syncytial virus replication
Date:5/5/2008

GALVESTON, Texas University of Texas Medical Branch at Galveston researchers have achieved promising results with a potential new weapon against respiratory syncytial virus, the most common cause of infant hospitalization in the United States.

In an effort to find an effective antiviral therapy for RSV, the scientists tested two types of complex, custom-designed molecule to interfere with the genetic machinery that RSV uses to replicate, or copy itself, within cells. Both of the so-called morpholino oligomers, created by Oregon-based AVI BioPharma, penetrated cultured human airway cells easily and produced only minimal toxicity. One of the two, designated AUG-2, significantly reduced RSV replication in both cell culture and mouse experiments.

Viral replication is one of the major pathogenetic processes of RSV, and we badly need a specific antiviral therapy, said UTMB Dr. Roberto Garofalo, senior author of a paper on the study to be published in the June issue of Molecular Therapy and now available in the Advance Online Publication section of the journals website. That's what an agent like this morpholino could give us.

RSV infects almost all children by age two, but normally causes only a cold-like upper respiratory infection. In some babies, however, it spreads to the lungs, where the inflammation it generates causes coughing, wheezing and extreme difficulty in breathing, a life-threatening clinical syndrome known as bronchiolitis.

Recent research by Garofalo and other investigators suggests that two key factors drive RSV bronchiolitis: an inflammatory overreaction by the cells that line the airways of the lungs, and a failure to respond to RSV by T lymphocytes (also known as T cells), immune system cells that ordinarily act to control viral infections.

Because a dangerous inflammatory response occurs so soon after RSV begins replicating in the lungs, Garofalo said, antiviral therapy by itself is unlikely to be suf
'/>"/>

Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
2. China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent
3. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
4. Peter Burg Appointed as Co-Chair of the Plaintiffs Steering Committee and the Executive Committee for the Gadolinium-Based Contrast Agents Product Liability Multi-District Litigation
5. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
6. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
7. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
8. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
9. IUPUI scientists report first 3-D view of anti-cancer agent
10. Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
11. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... from Boston University,s Slone Epidemiology Center have found ... risk for type 2 diabetes in African American ... American Journal of Epidemiology , is the ... neighborhood socioeconomic status and incidence of type 2 ... African-American women. , Type 2 diabetes is estimated ...
(Date:2/9/2010)... February 8, 2010- The research group of Dr. Franois ... de Montral (IRCM), in collaboration with the team of ... of Toronto) accomplished a technical breakthrough: they mapped all ... yeast Saccharomyces cerevisiae . The method used by ... has been published online today in the scientific journal ...
(Date:2/9/2010)... in infants born prematurely in the US, according to ... (LUHS). These findings were reported at the 30th Annual ... They also were published in the latest issue of ... , Researchers reported that CP is associated with inflammation ... inflammation is more common in premature births from preterm ...
(Date:2/9/2010)... , Feb. 9 The Quantum Foundation ... the School District of Palm Beach County that ... fit. The Robert Wood Johnson Foundation (RWJF) recently announced a ... and access to affordable healthy foods for children and families ... communities. Based on a rigorous selection process that drew ...
(Date:2/9/2010)... forms of the protein cyclin E renders the ... (ER+) breast cancers, researchers from The University of ... Clinical Cancer Research . , The M. ... professor in M. D. Anderson,s Department of Experimental ... Stringer Professor in Medical Oncology, found evidence that ...
Breaking Medicine News(10 mins):Health News:Neighborhood socioeconomic status and diabetes 2Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 2Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 3Health News:Incidence of cerebral palsy on rise in US 2Health News:Planting Seeds to Fight Childhood Obesity 2Health News:Low forms of cyclin E reduce breast cancer drug's effectiveness 2Health News:Low forms of cyclin E reduce breast cancer drug's effectiveness 3
... entry-level price point , , SALT ... SNCI ) the only U.S.-based publicly traded manufacturer of digital ... Velocity series. The Velocity 6 now becomes the latest product ... , , Sonic Innovations, CEO Sam ...
... get cosmetic surgery but either couldn,t afford it or were afraid ... out of cosmetic surgery with a nonsurgical facelift that,s extremely safe, ... could you ask for? , ... Coral Gables, FL ...
... announced its nominations for the prestigious "Super Dentist" award given to ... again nominated a top practitioner in the area of Cosmetic Dentistry. ... ... Michael McCarty of Austin Smiles was recently nominated as ...
... Foundation is creating a new inter-disciplinary research network to help ... aging society. In the middle of the next decade, ... of which is that those over age 60 will outnumber ... increasingly gray in subsequent decades, we are not well prepared ...
... could be key to new disease-fighting therapies , , THURSDAY, ... suggests inhibiting a protein that allows certain tumor cells ... treatments. , A study by Pierre Sonveaux and colleagues ... tumor cells use different fuel sources depending on whether ...
... 5, the Johns Hopkins Bloomberg School of Public Health and ... symposium to mark the 60th Anniversary of the Universal Declaration ... The Work Ahead of Us," will evaluate progress in public ... Navanethem Pillay, SJD, LLM, the United Nations High Commissioner for ...
Other Medicine News:Health News:Sonic Innovations Launches New Product to Meet Growing Consumer Need and Demand for Digital Hearing Aids 2Health News:Sonic Innovations Launches New Product to Meet Growing Consumer Need and Demand for Digital Hearing Aids 3Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 2Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 3Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 4Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:New MacArthur network to examine impact of aging society 2
(Date:2/9/2010)... Mass. , Feb. 9 STD Med, ... Stoughton, Massachusetts is pleased to announce the acquisition ... Bridgewater, Massachusetts . This is in addition to the current ... growing and advancing the company during these difficult financial times," ... this growth to the premise on which STD Med was ...
(Date:2/9/2010)... , Feb. 9 Volcano ... and manufacturer of precision intravascular therapy guidance tools ... coronary and peripheral vascular disease, announced today that ... device line from Lumen Biomedical. Volcano became the ... May 2009 . This acquisition reinforces Volcano,s ...
(Date:2/9/2010)... Calif. , Feb. 9 ... announced financial guidance for the full year 2010. ... $147 to $165 million .  In addition, ... in 2010, with earnings per share for the ... $0.02 , excluding any mark-to-market adjustments relating to ...
Breaking Medicine Technology:STD Med Inc. Acquires Facility for Manufacturing and Start-Ups 2Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 2Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 3Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 4Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 5ISTA Pharmaceuticals Announces 2010 Financial Guidance 2ISTA Pharmaceuticals Announces 2010 Financial Guidance 3ISTA Pharmaceuticals Announces 2010 Financial Guidance 4ISTA Pharmaceuticals Announces 2010 Financial Guidance 5Alcohol consumption may increase breast cancer recurrence risk 63050 1Alcohol consumption may increase breast cancer recurrence risk 63050 2Potential new heart attack biomarker uncovered 11085 1Potential new heart attack biomarker uncovered 11085 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 15138 1Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 15138 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 15138 3
... - King,Pharmaceuticals, Inc. (NYSE:KG) reported today that ... Altace (ramipril) 20mg and the,combination of ALTACE ... weekend at the American Society of Hypertension,Inc. ... 2007) in Chicago, Illinois. The clinical trial ...
... being presented today at Digestive Disease Week -, ... today,announced the presentation of data from a Phase ... improved bowel function,in patients with constipation- predominant irritable ... well tolerated with,a low incidence of adverse events. ...
Other Medicine Technology:King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 2King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 3King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 4King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 5Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 2Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 3Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 4
... Neonates to adults, the entire series of ... knowledge of the needs of care providers ... in the accuracy. You can see it ... in the performance, year after year. Every ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: